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ABSTRAK 
Pendahuluan: Dalam Limfoma Sel-B Besar Difus (DLBCL) yang baru 
didiagnosis, PET-CT 18F-FDG memang digunakan secara rutin di 
seluruh dunia bagi tujuan pengkelasan perubatan. Penglibatan sumsum 
tulang adalah penting dalam pengurusan dan keperluan terapeutik. 
Standard emas dalam pengambilan sumsum tulang dikenali sebagai 
biopsi sumsum tulang. Kajian kohort ini berperanan menilai PET-CT 18F-
FDG dalam pengesanan penglibatan sumsum tulang secara relatif 
berbanding kepada biopsi sumsum tulang. 
 
Objektif: Kajian ini dijalankan bagi tujuan untuk membuktikan 
penggunaan imbasan PET-CT 18F-FDG berguna dalam menilai 
penglibatan sumsum tulang dalam kes DLBCL selaras dengan biopsi 
sumsum tulang. 
 
Kaedah: Semua pesakit yang dirujuk dari rantau utara Malaysia yang 
baru didiagnos dengan DLBCL bagi tujuan pengkelasan tulang sumsum 
pra-kemoterapi. Semua pesakit yang dirujuk akan menjalani imbasan 
PET-CT 18F-FDG dan biopsi sumsum tulang sebelum rawatan 
kemoterapi diberikan. Kedua-dua ujian mesti dilakukan dalam 
jangkamasa yang tidak melebihi 60 hari.  
 
Keputusan: Daripada 28 pesakit yang dirujuk untuk kajian ini, 21 pesakit 
berjaya didaftarkan. Sejumlah 14 pesakit menunjukkan imbasan PET-
CT 18F-FDG negatif dan biopsi negatif, 3 pesakit menunjukkan imbasan 
 XIV 
PET-CT 18F-FDG positif dan biopsi positif dan 4 pesakit lain 
menunjukkan imbasan PET-CT 18F-FDG positif tetapi biopsi sumsum 
tulang negatif. Imbasan PET-CT 18F-FDG menunjukkan nilai ramalan 
negatif 100% dan sensitiviti 100%. Terdapat persetujuan yang 
sederhana antara skan PET-CT 18F-FDG dan BMB yang menunjukkan 
kesesuaian penting (kappa k-value: 0.500, p <0.008). 
 
Kesimpulan: Imbasan PET-CT 18F-FDG dalam pola pengambilan 
selektif (negatif / multifokal / fokus)	dapat memainkan peranan sebagai 
alternatif bagi teknik invasif seperti biopsi sumsum tulang dalam 
penglibatan pengkelasan sumsum tulang dalam kes DLBCL. 	
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ABSTRACT 
Title : The role of 18F -FDG PET-CT in assessing bone marrow involve-
ment in Diffuse Large B-Cell Lymphoma (DLBCL).  
Introduction: In newly diagnosed DLBCL, 18F-FDG PET-CT is routinely 
used worldwide for staging. Bone marrow involvement is crucial in order 
for therapeutic purposes. Bone marrow biopsy is known as the gold 
standard in ruling out bone marrow involvement. This cohort study 
hereby assesses the role of 18F-FDG PET-CT in the detection of bone 
marrow involvement comparatively to bone marrow biopsy. 
Objective: The aim of this study is to justify the usage of 18F-FDG PET-
CT scan in assessing bone marrow involvement in DLBCL as appose to 
bone marrow biopsy. 
 
Methods: All newly diagnosed DLBCL cases within the northern region 
of Malaysia was referred for pre-chemotherapy bone marrow staging.  
All subjects underwent both 18F-FDG PET-CT scan and bone marrow 
biopsy before chemotherapy treatment was given. Both studies were 
done between an interval of not more than 60 days.   
 
Results: Out of 28 subjects referred for this study, 21 subjects were 
successfully enrolled. A total of 14 subjects showed a negative 18F-FDG 
PET-CT scan and BMB, 3 subjects showed a positive 18F-FDG PET-CT 
scan and BMB and another 4 subjects showed a positive 18F-FDG PET-
CT scan but negative BMB. 18F-FDG PET-CT scan showed a negative 
 XVI 
predictive value of 100% and sensitivity of 100%. There was moderate 
agreement between 18F-FDG PET-CT scan and BMB which showed sig-
nificant concordance (kappa k-value: 0.500, p<0.008). 
 
Conclusion: 18F-FDG PET-CT scan in selective pattern of uptake 
(negative / multifocal / focal) is an alternative method comparatively to 
BMB for assessing baseline bone marrow involvement among DLBCL 
patients. 
 
 1 
1.0 Introduction & Literature review 
      Lymphomas which is part of the neoplasm group comprising of 
Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) in 
which the management and prognostic value is dependent on the stage, 
severity and extension of the lymphoma (Pelosi et al., 2008). Diffuse 
large B-cell lymphoma (DLBCL) is the most common form of lymphoma 
and it attributes up to 58% with an overall  annual incidence of 25000 
cases (Berthet et al., 2013). Statistically DLBCL contributes to 5% of all 
type of malignancies (Adams et al., 2014a). Two studies in Malaysia 
written by Peh et al. (2003);Chang et al. (2006) agreed that DLBCL had 
a higher prevalence compared to other types NHL. Statistically, in 
Horesh and Horowitz (2014) they revealed a male predominance in NHL 
cases within the United States, United Kingdom and Europe which is 
similar to the findings of an article written by Nair et al. (2016) where 
there is a higher male to female ratio globally inclusive of Asian 
countries. In Fadilah (2009) she also acknowledges a higher prevalence 
in male gender patients compared to women for NHL in Malaysia. She 
also highlighted NHL being the 3rd commonest cancer in males less than 
50 years of age followed by the 10th commonest in males more than 50 
years of age. Quite different for the female gender which is lesser and 
contributes to being the 10th commonest cancer in the age group less 
than 50 years old and 14th place vice versa. This suggests that NHL is 
more aggressive in males compared to females. 
            DLBCL is a highly aggressive disease that needs to be detected 
and treated immediately. The disease’s clinical course is highly variable 
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based on the various subtypes and in most cases presented late at 
Stage III or IV (Alizadeh et al., 2000) with up to 40% of patients relapsing 
after the 1st line chemotherapy (Johnson et al., 2015).  
Multiple risk factors contributing to the incidence of DLBCL includes 
autoimmune disease, immunosuppressive disease such as human 
immune-deficiency virus infection, hepatitis C virus seropositivity, history 
of lymphoma in family, occupational exposure, and increased body mass 
as a young adult (Tilly et al., 2015). According to its pathogenesis it 
arises either from the B-cell germinal centre or from a later differentiation 
of an aggressive mature B lymphocytes malignancy (Alizadeh et al., 
2000). 
       Since early 2014, most physicians often refers to the European 
Society of Medical Oncology (Tilly et al., 2015) clinical practice guideline 
as the standard reference in diagnosing DLBCL (Tilly et al., 2015). 
Physical examination, performance status (Zhou et al., 2014), 
assessment of B symptoms, haematological laboratory references 
including immuno-phenotypic investigations as well as protein 
electrophoresis, and imaging work groups has played a major part in the 
making of treatment decisions. The initial staging was initially made 
based on the Ann Arbor classification which was initially implemented in 
the 1970’s followed by further alteration in the 1980’s known as Modified 
Ann Arbor (Cotsworlds) as seen in Table 1.1 (Johnson et al., 2015). The 
International Prognostic Index (IPI) group was introduced to determine 
prognostic outcomes of patients (Berthet et al., 2013) as seen in Table 
1.2. In the IPI index, lymphoma was classified into scorings per 5 
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characteristics where one of them includes bone marrow involvement 
which is categorized as extra-nodal sites and is used to risk stratify and 
identify risk discrete categories (Khan et al., 2013; Zhou et al., 2014). 
Treatment then given to NHL patient’s was decided based on age and 
IPI index which was classified into young low-risk without bulky disease 
(IPI=0), young low-risk with bulky disease (IPI=0), young low-
intermediate risk (IPI=1), young high and high-intermediate risk (IPI=2), 
patient aged 60-80 years old, patient >80 years old and CNS 
involvement prophylaxis (Tilly et al., 2015). In 2014, a revision of Ann 
Arbor staging (Lugano 2014) as shown in Table 1.3, was done in order 
to achieve more congruous therapeutic response (Van Heertum et al., 
2017). 
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Stage Description 
I Single lymph node group 
II Multiple lymph node groups on same side 
of diaphragm 
 
III Multiple lymph node groups on both sides 
of diaphragm 
 
 
IV Multiple extranodal sites or lymph nodes 
and extranodal sites  
X Bulk >10cm 
E Extranodal extension or single isolated 
site of extranodal disease 
A/B B symptoms: weight loss >10%, fever, 
drenching night sweats 
Table 1.1: Ann Arbor Classification (Cotsworlds). 
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    *Age-adjusted IPI in patients less than 60 years old  
 
 
 
 
 
 
Risk Factors 
(Serum LDH > normal, Stage III – 
IV, Performance status 2-4) 
Risk Categories 
Estimated 3 year 
overall survival (95% 
CI) 
0 
1 
2 
3 
Low  
Low intermediate  
High intermediate  
High 
98% 
92% 
75% 
75% 
Risk Factors 
(Age > 60 years, Serum LDH > 
normal, Stage III – IV, 
Performance status 2-4, 
Extranodal site > 1) 
Risk Categories 
Estimated 3 year 
overall survival (95% 
CI) 
0-1  
2 
3 
4-5 
Low  
Low intermediate  
High intermediate  
High 
91% 
81% 
65% 
59% 
Table 1.2: International Prognostic Index (IPI)  
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Stage Involvement 
Limited 
I 
 
 
 
One node @ group of adjacent nodes 
*Extranodal (E) status = single extranodal lesion without nodal 
involvement  
II 
 
 
 
II bulky * 
2 @ more nodal groups on the same side of the 
diaphragm 
*Stage I and II by nodal extent with limited contiguous extranodal 
involvement 
as above with “bulky” disease 
Advanced 
III 
 
 
Nodes on both sides of the diaphragm; nodes above the 
diaphragm with spleen involvement 
IV Additional non-contigous  
Table 1.3 Modified Ann Arbor (Lugano 2014) 
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           Bone marrow involvement affects more commonly in NHL in 
particular DLBCL subtypes with incidence up to 17% (Carr et al., 1998). 
It contributes to 1 point in the IPI index score and is found in up to 15% 
of newly diagnosed DLBCL cases (Chen et al., 2018). The involvement 
in the marrow is usually categorised into large cells for example 
concordant (prominent component of large transformed high grade 
lymphoma) BMI or small cells for example in discordant (small lymphoid 
cells with cleaved nuclear contours suggestive of coexisting low grade 
lymphoma) BMI (Chung et al., 2007; Adams and Kwee, 2015). In 
another study by Adams et al. (2015b) lymphomatous cells which 
infiltrate the bone marrow results from a haematogenous spread or 
adjacent soft tissue extension and is more aggressive which changes 
the prognostic and therapeutics consequences. In a study by Sehn et al. 
(2011) their findings were in tandem with other previous studies that 
concordant bone marrow involvement has poor prognostic value  for 
overall survival. The study also suggested a significant prolonged PFS 
(patient free survival) value by adding rituximab when an early bone 
marrow involvement is detected (Sehn et al., 2011). Therefore, the 
accuracy in BMI staging is paramount in order for therapeutic strategy 
optimization (Berthet et al., 2013). 
       For diagnosing lymphoma, surgical excisional biopsy remains to be 
the optimal choice as it allows nodal assessment and dispenses 
adequate sample for phenotypic and molecular studies (Tilly et al., 
2015). In assessing BMI, BMB or also known as marrow trephine biopsy 
plays a pivotal role in routine staging (Carr et al., 1998). Furthermore, 
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this diagnostic intervention was known to be the gold standard in 
determining bone marrow status (Berthet et al., 2013). In Adams et al. 
(2015a), BMB is a definitive proof and known to aid in diagnosing DLBCL 
that has no appropriate extramedullary lesion for biopsy. The detection 
of BMI through BMB histologically has acclaimed an unfavourable 
prognostic factor. Thus, by obtaining histologically proven BMI results 
via BMB, it indicates an advanced disease assisting to a selection of a 
more intense therapeutic regime. Its ability to occasionally diagnosed 
other bone marrow disease or alterations is also an advantage (Adams 
et al., 2015c). However, it is a blinded painful invasive procedure which 
can lead to risks of pain, anxiety, haemorrhage and infection 
(Abdelrahim et al., 2018). Inadequate sampling due to factors such as 
wrong biopsy site and technique also plays a major part of downside in 
bone marrow trephine biopsy (Abdelrahim et al., 2018). In previous 
studies, particularly in high grade NHL, unilateral iliac crest trephine 
biopsy consistently shows unreliability and discrepancy reaching up to 
50% (Carr et al., 1998). In Adams et al. (2015a), the study showed a low 
positive marrow histology incidence of only 17%. Apart from the 
limitation of high numbers of sampling errors, the procedure is also 
known to be time consuming (Adams et al., 2015c).  
            In the latest consensus established by international conference 
of malignant lymphoma (Lugano classification) working groups, the role 
of Fluorine-18 Fluorodeoxyglucose positron emission tomography – 
computed tomography (18F-FDG PET-CT) scan is the current gold 
standard of staging and restaging in lymphoma (Tilly et al., 2015). This 
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allows physiological response assessment based on the tumour 
metabolism itself (Van Heertum et al., 2017). 18F (Fluorine-18) is a 
positron emitting isotopes used commonly in oncology for primary 
staging and tumour treatment response. (Adams et al., 2014a). It is a 
glucose analogue whereby the uptake is increased in the tumour cells in 
relation to raised glucose transfer (Carr et al., 1998). 18F enters the cells 
through sodium-independent glucose transporter (GLUT-1, GLUT-3 and 
GLUT-12) via facilitated diffusion. After entering the cells, it undergoes 
the normal glucose metabolic pathway where hexokinase 
phosphorylates and forms itself into 2- 18F fluoro-2-deoxy-d-glucose-6-
phosphate (18F FDG-6P). At this point, the 18F metabolic pathway defers 
as compared to the previous normal glucose pathway. Firstly, the fruc-
tose-6-phosphate is converted from glucose-6-phosphate by phos-
phoglucose isomerase, then further irreversibly phosphorylates to fruc-
tose-1,6-biphosphate by the phosphofructokinase and further continues 
in the glycolytic pathway. However, compared to normal glucose path-
way that undergoes glycolysis, the presence of charged phosphate 
group causes the 18F FDG-6P to be trapped and unable to leave the cell. 
Therefore, as tumour cells glycolysis rate increases, 18F FDG-6P accu-
mulates in tumours than normal tissue.  
        In PET, a study is evaluated based on the size and intensity where 
visual assessment by Standard Uptake Value (SUV) is used to 
determine any abnormal FDG accumulation seen in 18F-FDG PET-CT 
images. This is the measurement uptake of the tumour based on a 
distribution volume. The volume of interest which is equivalent to the 
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voxel with highest uptake in a tumour or lesion is analysed using 
maximum SUV measure SUVmax in which must be identified on 
reconstructed initial 18F-FDG PET-CT images (Boellaard et al., 2010). 
CT on the other hand gives morphological and anatomical visualization 
for better accuracy of anatomical correlation, degree and lesion 
characterisation by 18F-FDG PET-CT. Therefore, integrated PET-CT 
carries out morphological and functional properties in one single imaging 
(Boellaard et al., 2010). For bone marrow involvement in lymphoma, 
there will be increased bone marrow 18F-FDG PET-CT uptake exceeding 
liver FDG uptake (Adams et al., 2014a).  
           In lymphoma, 18F follows the red marrow and is further distributed 
throughout the skeletal system (Adams et al., 2014a). Therefore 18F-
FDG PET-CT is able to provide high-quality whole-body imaging for 
primary staging, remission assessment and treatment of lymphoma 
(Carr et al., 1998; Cheson et al., 2007). 18F-FDG PET-CT scan is a non-
invasive technique, well known to be highly sensitive in lymphoma 
disease especially in DLBCL (Pregno et al., 2012). One of the other 
advantages is that it promotes visualization of the whole bone marrow in 
comparison to restricted site of BMB (Adams and Kwee, 2015) hence 
being able to achieve simultaneous staging of extramedullary disease 
(Adams et al., 2015c) . In assessing the BMI in 18F-FDG PET-CT, the 
pattern of uptake plays a major role in determining diagnostic and 
prognostic value in DLBCL cases. In Chen et al. (2018) they reported 
the implication of BMI in patients prognosis depends on the type of 
uptake seen on 18F-FDG PET-CT scan. Type of uptake pattern was 
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defined as focal (SUVmax is more than liver), diffuse (homogenously 
diffuse SUVmax more than liver) and normal (homogenously diffuse 
SUVmax less than liver). Their study demonstrated focal uptake of pattern 
as an independent predictor for inferior outcomes suggesting BMB is no 
longer necessary in the DLBCL management. Tilly et al. (2015) the focal 
pattern of uptake in 18F-FDG PET-CT is highly specific with better 
sensitivity compared to BMB in DLBCL suggesting that BMB is no longer 
required in determining BMI. However, not all FDG avid bone marrow 
abnormality represents lymphoma as explained in Adams et al. (2015c) 
alongside other limitations of 18F-FDG PET-CT such as lack of histologic 
material and the use of ionizing radiation.  
      Other modalities such as CT scans and magnetic resonance imaging 
(MRI) may also be utilised in detecting BMI in DLBCL cases. In most 
practices, CT scan is done in the initial staging of lymphoma disease. In 
Ahmed et al. (2013), he explained that the presence of skeletal lesions 
seen on CT are likely due to cortical bone metastasis. This is usually 
seen in the advanced stages of the disease with variable osseous 
appearances (lytic/sclerotic/mixed) seen on CT followed by further 
sclerosis development seen post chemo-radiotherapy (Johnson et al., 
2015). In an article by Adams et al. (2015d) CT shows lesser sensitivity 
in BMI detection and the presence of tumour-induced cortical bone 
destruction showed no prognostic implication in DLBCL as osteolysis is 
rare in most patients with BMI. Thus, CT scan is more anatomical and 
preferably used for better delineation of lymphadenopathy and its 
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measurements, detection of thrombosis/compression as well as 
radiation planning (Tilly et al., 2015).          
           Another modality known as MRI can also be used for baseline 
staging of BMI in lymphoma. In MRI, it is able to provide high spatial 
resolution images in detecting BMI which shows a T1-hypointense mass 
in MRI images as described in Adams et al, (2013);Johnson et al, (2015). 
Large studies like Adams et al. (2013), concluded that there is not much 
difference between MR imaging and 18F-FDG PET-CT scan in staging 
for BMI. Like 18F-FDG PET-CT scan it is equivalently sensitive with a 
favourable negative predictive value (NPV). However, MRI imaging 
showed lesser sensitivity in high grade lymphoma than in low grade 
lymphoma compared to 18F-FDG PET-CT imaging (Adams et al., 2013). 
           In most previous studies, evidence has suggested that BMB may 
be replace by 18F-FDG PET-CT in Hodgkin’s lymphoma. The low 
incidence rate of BMI and lack of treatment consequences in advanced 
HL disease makes it more permissible for BMB to be omitted in 
assessing BMI provided 18F-FDG PET-CT scan is done (Adams et al., 
2015c). The value is obsolete and has already been practiced in some 
centres. (El-Galaly et al., 2014). In Cheson et al. (2007), the study 
recommends 18F-FDG PET-CT scan to be carried out for pre-treatment 
patients in potentially curable lymphomas which is commonly FDG avid, 
such as DLBCL and HL in order of better delineation of the disease.  In 
previous studies such as Berthet et al. (2013) involving a homogenous 
population of 133 patients which described BMI assessment done by 
18F-FDG PET-CT scan is superior in diagnostic capability and stratifying 
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patient’s prognosis compared to BMB with a sensitivity of 93.9% vs 
24.2% and similar specificity of 99% vs 100% in newly diagnosed 
DLBCL. Unlike Adams et al. (2014b), his study showed that both 
quantitative as well as qualitative 18F-FDG PET-CT scan in assessing 
BMI are inferior to BMB in prognosis stratification with a sensitivity of 
68.1%. These conflicting results as well as limitations to cost, availability 
and limited study produced during their time were the main reasons as 
to why BMB was still mandated for assessing BMI (El-Galaly et al., 
2014). However, in further recent studies by Adams et al. (2014a) based 
on a systemic and meta-analysis review he reported that evidence 
suggest 18F-FDG PET-CT scan is a substitute for BMB in diagnosing 
BMI in DLBCL. Nevertheless, in Chen-Liang et al. (2015), they too 
proposed that a BMB is no longer required in a positive focal pattern 18F-
FDG PET-CT scan (classified stage IV). Another article by El Karak et 
al., (2017), he suggested to omit the need for BMB in a negative for BMI 
18F-FDG PET-CT scan in view of the high NPV. In a recent study by 
Chen et al., (2018), in view of BMB’s unfavourable accuracy and 
limitation of predicting patient prognosis compared to 18F-FDG PET-CT 
scan, the role of BMB is unnecessary in assessing BMI.  
        Despite multiple studies done in assessing BMI with 18F-FDG PET-
CT scan, the role of pre-chemotherapy 18F-FDG PET-CT in assessing 
BMI in Malaysia has yet to be enforced in view of limited sources i.e. 
limited availability of PET-CT scans, affordability and awareness by 
primary physician teams. All lymphoma patients in Malaysia is still 
subjected to BMB despite current literature suggests and allows 
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practitioners to be more selective in deciding which patient is more 
suitable for BMB if the role of 18F-FDG PET-CT is taken into 
consideration. The motive of this study is to look into the ability of 18F-
FDG PET-CT as well as to collate the sensitivity and specificity between 
18F-FDG PET-CT scan and BMB in assessing BMI specifically in DLBCL.  
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2.0 RATIONALE/BENEFITS OF THE STUDY  
      This research is conducted to determine the role and significance 
of 18F-FDG PET-CT scan in assessing BMI for DLBCL disease. With 18F-
FDG PET-CT imaging, it has the ability to represent as another 
replacement tool besides BMB for detecting the presence of BMI in 
DLBCL. Detection of BMI via 18F-FDG PET-CT scan imaging, could 
possibly be more time saving and more convenient for the patient as it 
can minimize the need for an invasive procedure. 
 
2.1 Aim  
      To justify the use of 18F-FDG PET-CT scan in assessing bone 
marrow involvement in DLBCL as appose to bone marrow biopsy. 
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2 2. Objectives  
 
       2.2.1 General Objective:  
. To validate the presence of BMI in DLBCL based on routine 
staging 18F-FDG PET-CT scan, is as sufficiently accurate as 
compared to BMB. 
 
  2.2.2 Specific Objectives:  
. To describe into the demographics of patients with DLBCL that 
are referred for 18F-FDG PET-CT in Hospital Pulau Pinang. 
 
. To compare the sensitivity & specificity between 18F-FDG PET-
CT and bone marrow biopsy in detection of BMI.  
 
. To determine the characteristics of 18F-FDG uptake that positively 
demonstrates BMI. 
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2.3 Hypothesis Statement  
• Null hypothesis: The use of 18F-FDG PET-CT does not serve as 
an alternative method comparatively to bone marrow biopsy for 
baseline bone marrow assessment in Diffuse Large B-cell lym-
phoma patients.   
 
• Alternate hypothesis: The use of 18F-FDG PET-CT does serve as 
an alternative method comparatively to bone marrow biopsy for 
baseline bone marrow assessment in Diffuse Large B-cell lym-
phoma patients. 
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3.0 METHODOLOGY  
  3.1 Study Design, Study location and Study Period  
     A prospective study with universal sampling method was carried out 
in the Nuclear Medicine Department, Hospital Pulau Pinang from the 
period of November 2016 to February 2018. 
 
 3.2 Study Sample  
      Subjects referred to Hospital Pulau Pinang who were recently di-
agnosed with DLBCL were the reference population. Source population 
were subjects who were referred to the Nuclear Medicine Department, 
Hospital Pulau Pinang for first diagnostic pre-chemotherapy 18F-FDG 
PET-CT scan. The subjects with newly diagnosed DLBCL who came to 
Nuclear Medicine Department, Hospital Pulau Pinang for first diagnos-
tic18F-FDG PET-CT scan was the sampling population and the study 
participants were those whom have consented to participate in this study 
and fulfilled the inclusion and exclusion criteria. 
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3.3 Inclusion and Exclusion Criteria   
3.3.1 Inclusion criteria:  
. Adult (>18 years old) patients newly diagnosed with Diffuse Large 
B-cell lymphoma (DLBCL). 
. Pre-treated Diffuse Large B-cell lymphoma (DLBCL) and 
underwent 18F-FDG PET-CT as well as bone marrow biopsy. 
 
3.3.2 Exclusion criteria:  
. Subjects previously known & treated for lymphoma. 
. Subjects which have passed interval between first FDG-PET/CT 
and BMB of more than 60 days. 
. Subjects who have received hematopoietic growth factor 
injections less than 48 hours before the first 18F-FDG PET/CT 
scan. 
. Subjects with other primary malignancies. 
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3.4 Data Collection   
      All referrals for pre-staging 18F-FDG PET-CT in newly diagnosed 
Diffuse Large B-cell Lymphoma (DLBCL) were screened by the prin-
cipal investigator (PI). Base on the referral forms that was sent, those 
who fulfilled the inclusion and exclusion criteria were recruited to par-
ticipate in this study and informed consents were taken. Any bone 
marrow biopsy that was done prior to the scan, was given 18F-FDG 
PET-CT appointment within the period of 60 days following the 
biopsy. A delay period interval of more than 60 days may result in 
morphological histopathological changes leading to invalidity of 
results (Dupas et al., 2013). PET-CT scan appointment is scheduled 
48 hours after any hematopoietic growth factor injections to avoid 
false positive bone marrow uptake in PET-CT scan secondary to 
inflammatory response (Hanaoka et al., 2011). Subjects preparation 
for PET-CT was run per department protocol. Subjects was advised 
to reduce carbohydrates in their meal and all patients fasted 4-6 
hours before scan day to limit the impact and avoid glucose to 
compete with 18F-FDG during scan. Instruction to avoid strenuous 
exercise for few days before study was also given to reduce muscle 
uptake will also be conveyed.  
       On the day of the appointment, subjects were clerked and ex-
amined to ensure compliance to the preparation and clinical data as 
well as written consent were obtained. Subjects with diabetes was 
carefully scheduled in the morning before taking insulin and those 
with metformin medication was advised to withheld medication from 
 21 
morning of the scan to decrease bowel background activity related to 
the drug. Before injection of FDG, all subjects was ensured that their 
blood glucose levels were less than 11 mmol/L as indicated in the 
department protocol.  
          A 20’gauge size branula was then inserted and subjects was 
given radiopharmaceutical intravenous injection 18F-FDG per the 
routine standard dose (6MBq/kg; 10-15mCi). Each subject was 
explained that 18F-FDG causes no significant risks whereby 18F-FDG 
has been widely used with high safety profile. However, subjects 
were explained regarding small possible hypersensitivity reactions 
such as itchiness, skin rashes, hypotension, chills, nausea, fever and 
vomiting. Bleeding, bruising, discomfort, infection and/or pain at 
needle site caused by the needle puncture for injection of 
radiopharmaceutical was also explained to the subject. Thus, 
immediate medical care and attention was ensured to be provided if 
such events occur. 
             The standard practice for evaluation and staging of DLBCL 
in HPP is by PET CT scan using a radiopharmaceutical agent of 18F. 
Imaging is done 45-60 minutes post injection (longer delays increase 
tumour to background ratios) which involves entire base of brain till 
upper thigh. PET (GE discovery ST) scanning was done from mid 
femur to the vertex with 3 min per bed position. A transmission date 
acquisition of 40-minutes attenuation data acquisition using built in 
CT scanner is done along with 1-hour attenuation data acquisition 
using radioactive sources with 2D mode (in septa) collimator and 
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30% energy window of 511kev. The low-dose CT data was used for 
attenuation correction of the PET images. Scan results were seen by 
two experienced appointed specialists in the same centre and both 
of them was involved in assessing BMI in the scans based on their 
uptake. Any disagreement in the results was resolved by a third 
reader a senior consultant of Nuclear Medicine to attain an 
anonymous definite result. Results of the findings were then 
compared with traced BMB findings (acquired from Pathology 
Department HPP and Haematology Department HPP). Study was 
suspended or terminated once 18F-FDG PET-CT scan and bone 
marrow biopsy by haematology team was completed.  
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3.5 Bone marrow involvement and uptake 
The assessment of BMI is done by utilising 2 different methods: 
1. Qualitative method  
2. Quantitative method  
 
3.5.1 Qualitative method: 
• Interpretation by a specialist appointed - blinded to BMB and 
18F-FDG PET-CT scan results  
• Any FDG uptake more than liver FDG uptake is interpreted as 
abnormal (= lesion). 
Based on a the study by (Adams et al., 2015a), bone marrow 
involvement is classified as:  
• Uni-focal: 1 circumscribed lesion  
• Multifocal: > 1 circumscribed lesion – Figure 3.1 
• Diffuse: Whole bone marrow (rather than a single location) - 
Figure 3.2 
• Focal & Diffuse: Circumscribed & Diffused area – Figure 3.3 
• Negative : No lesions / Diffuse bone marrow uptake with 
SUVmax less than liver – Figure 3.4 
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Figure 3.1. Multifocal type of uptake 
 
 
